PBYI: Puma Biotechnology, Inc.
About
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Key Details
Market Cap
$134.50M
P/E Ratio
5.77
1Y Stock Return
-28.83%
1Y Revenue Growth
6.30%
Dividend Yield
0.00%
Price to Book
1.9
Strategies that include PBYI
Stock's related to PBYI
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BLNK | 34.29% | $156.82M | -57.53% | 0.00% |
| TCMD | 32.44% | $378.43M | +24.66% | 0.00% |
| OUST | 31.90% | $448.93M | +87.53% | 0.00% |
| CERS | 31.74% | $312.00M | -0.59% | 0.00% |
| LAC | 31.70% | $815.32M | -47.03% | 0.00% |
| EDIT | 31.66% | $204.72M | -75.49% | 0.00% |
| UFCS | 28.70% | $696.15M | +35.19% | 2.34% |
| CPS | 28.65% | $244.48M | -24.67% | 0.00% |
| ARRY | 28.25% | $926.85M | -60.03% | 0.00% |
| PSTX | 27.96% | $269.98M | +6.13% | 0.00% |
| SHLS | 27.14% | $691.80M | -70.53% | 0.00% |
| BDTX | 27.01% | $144.29M | +14.35% | 0.00% |
| EHAB | 26.91% | $365.57M | -26.27% | 0.00% |
| MCFT | 26.58% | $344.65M | -0.29% | 0.00% |
| TMHC | 26.52% | $7.19B | +55.90% | 0.00% |
| EWCZ | 26.48% | $281.81M | -57.40% | 0.00% |
| HNI | 26.46% | $2.62B | +39.78% | 2.40% |
| MTX | 26.44% | $2.54B | +28.39% | 0.52% |
| U | 26.40% | $7.98B | -30.33% | 0.00% |
| PII | 26.24% | $3.67B | -26.50% | 4.03% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AFL | -<0.01% | $61.74B | +35.69% | 1.35% |
| JNJ | 0.04% | $368.37B | +1.24% | 3.18% |
| ABBV | 0.06% | $294.35B | +20.07% | 3.72% |
| MFC | 0.06% | $57.06B | +70.70% | 3.59% |
| AHCO | -0.09% | $1.31B | +17.07% | 0.00% |
| KMB | -0.09% | $45.22B | +11.57% | 3.58% |
| TXO | 0.11% | $737.26M | -1.80% | 13.22% |
| NRG | 0.12% | $19.22B | +109.87% | 1.71% |
| LW | 0.13% | $10.70B | -23.51% | 1.93% |
| UEIC | -0.13% | $148.52M | +43.22% | 0.00% |
| BP | -0.14% | $77.24B | -18.61% | 6.32% |
| AMP | 0.16% | $54.58B | +61.67% | 1.03% |
| TEO | 0.17% | $1.69B | +87.97% | 0.00% |
| EQNR | 0.19% | $64.72B | -22.63% | 5.56% |
| MUR | -0.19% | $4.74B | -23.99% | 3.70% |
| TRV | -0.19% | $58.86B | +48.10% | 1.59% |
| LPTH | 0.19% | $62.27M | +33.05% | 0.00% |
| UAN | 0.20% | $753.51M | -1.90% | 9.38% |
| NTNX | -0.21% | $18.33B | +70.72% | 0.00% |
| HUM | -0.22% | $33.45B | -45.22% | 1.25% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DOGZ | -16.39% | $614.77M | +1,372.26% | 0.00% |
| LITB | -14.91% | $35.48M | -75.45% | 0.00% |
| CB | -12.02% | $114.43B | +26.00% | 1.24% |
| MSDL | -11.89% | $1.83B | +0.66% | 7.26% |
| LMT | -11.86% | $126.40B | +18.99% | 2.36% |
| PRPO | -11.27% | $9.10M | -13.65% | 0.00% |
| PGR | -11.00% | $149.10B | +57.29% | 0.45% |
| TCTM | -10.62% | $8.10M | -42.99% | 0.00% |
| CYD | -10.33% | $364.46M | -2.94% | 4.26% |
| WMT | -10.06% | $696.11B | +66.69% | 1.38% |
| CYCN | -10.05% | $4.77M | -16.19% | 0.00% |
| PULM | -8.98% | $19.83M | +202.98% | 0.00% |
| EW | -8.95% | $41.40B | +4.84% | 0.00% |
| CHD | -8.55% | $27.18B | +19.50% | 1.03% |
| CIG | -8.52% | $3.88B | +7.91% | 0.00% |
| K | -8.45% | $27.77B | +52.50% | 2.79% |
| GIS | -8.09% | $34.85B | -2.91% | 3.78% |
| XOS | -7.45% | $30.51M | -57.24% | 0.00% |
| CCAP | -7.42% | - | - | 8.70% |
| SOC | -7.15% | $1.93B | +74.70% | 0.00% |
ETF's related to PBYI
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VGLT | -0.16% | $12.70B | 0.04% |
| TLT | -0.30% | $57.46B | 0.15% |
| IBD | 0.38% | $330.68M | 0.44% |
| LGOV | -0.39% | $607.48M | 0.67% |
| XOP | 0.41% | $2.58B | 0.35% |
| BSCO | 0.45% | $2.35B | 0.1% |
| SCHQ | 0.46% | $762.08M | 0.03% |
| SPTL | 0.53% | $10.33B | 0.03% |
| HDRO | 0.55% | $164.26M | 0.3% |
| PGHY | 0.75% | $141.95M | 0.35% |
| TLH | 0.87% | $7.01B | 0.15% |
| TBIL | 0.88% | $4.38B | 0.15% |
| CCOR | 0.89% | $109.04M | 1.18% |
| GCC | -0.92% | $133.23M | 0.55% |
| IAK | 0.95% | $760.79M | 0.39% |
| KCCA | 1.08% | $220.51M | 0.87% |
| IGBH | 1.10% | $93.85M | 0.14% |
| DXJ | 1.12% | $3.71B | 0.48% |
| PXE | 1.18% | $117.58M | 0.63% |
| FCG | -1.22% | $395.85M | 0.6% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -23.42% | $388.04M | 1.43% |
| TAIL | -14.09% | $67.98M | 0.59% |
| VIXY | -12.74% | $195.31M | 0.85% |
| EQLS | -11.29% | $76.08M | 1% |
| DBC | -9.20% | $1.39B | 0.87% |
| USCI | -9.14% | $185.47M | 1.07% |
| HIGH | -8.60% | $302.78M | 0.51% |
| BCI | -8.60% | $1.20B | 0.26% |
| BOXX | -8.39% | $4.43B | 0.1949% |
| WEAT | -7.95% | $120.27M | 0.28% |
| FLDR | -7.83% | $595.01M | 0.15% |
| GSG | -7.80% | $914.42M | 0.75% |
| DBE | -7.76% | $50.13M | 0.77% |
| PDBC | -7.68% | $4.40B | 0.59% |
| BCD | -7.49% | $245.02M | 0.3% |
| USDU | -7.38% | $201.97M | 0.5% |
| EDV | -7.27% | $3.88B | 0.06% |
| CORN | -7.26% | $61.12M | 0.2% |
| AGZD | -7.20% | $142.76M | 0.23% |
| COMT | -7.06% | $829.06M | 0.48% |
News
Yahoo
Subjects in the trial are required to provide blood and tissue samples for biomarker analysis.
Yahoo
LOS ANGELES, November 20, 2024--Puma Biotechnology has initiated a clinical trial of alisertib with endocrine therapy in patients with HR+ HER2-negative metastatic breast cancer.
Yahoo
Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) strong earnings report was rewarded with a positive stock price move. We...
Yahoo
Puma Biotechnology ( NASDAQ:PBYI ) Third Quarter 2024 Results Key Financial Results Revenue: US$80.5m (up 44% from 3Q...
Yahoo
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance. Stock rallies.
Yahoo
Puma Biotechnology Inc (PBYI) reports a significant revenue increase and outlines future business development opportunities amidst ongoing challenges.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.